|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Consolidated Investment Entities | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Consolidated Investment Entities | ||||||||||||||||||||
| Market risk benefits | ||||||||||||||||||||
| Separate account assets | ||||||||||||||||||||
| Receivables | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Consolidated Investment Entities | ||||||||||||||||||||
| Deferred acquisition costs | ||||||||||||||||||||
| Restricted and segregated cash and cash equivalents | ||||||||||||||||||||
| Total restricted and segregated cash and cash equivalents | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Consolidated Investment Entities | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Policyholder account balances, future policy benefits and claims | ||||||||||||||||||||
| Market risk benefits | ||||||||||||||||||||
| Separate account liabilities | ||||||||||||||||||||
| Customer deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Total short-term borrowings | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Consolidated Investment Entities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Ameriprise Financial | ||||||||||||||||||||
| Consolidated Investment Entities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Common shares ($0.01 par value; shares authorized, 1,250,000,000; shares issued, 338,609,083 and 338,058,287, respectively) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury shares, at cost (251,625,431 and 246,794,407 shares, respectively) | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net of tax | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...